pipeline-prospector-insert
X

Find Clinical Drug Pipeline Developments & Deals for Fadraciclib

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            University of Edinburgh

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Fadraciclib

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Novocure

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration April 20, 2020

            Details:

            The parties will assess Cyclacel’s fadraciclib and seliciclib , its clinical stage CDK2/9 inhibitors, for their suitability for use in safety and efficacy studies in COVID-19 patients.